Flúbrómazepam 10 mg kúlur
€13.95 – €219.95Verðbil: €13.95 til €219.95
* Upplýsingarnar á þessari síðu eru samantekt og eru ekki ætlaðar til að ná yfir allar tiltækar upplýsingar um þetta lyf. Þær fjalla ekki um alla mögulega notkun, leiðbeiningar, varúðarráðstafanir, milliverkanir lyfja eða aukaverkanir og koma ekki í stað sérfræðiþekkingar og mats heilbrigðisstarfsmanns.
Flubromazepam experience 10 MG pellets
Flubromazepam experience pellets contain 10 MG of active substance (Flubromazepam).
Flubromazepam 10 MG pellets are produced in-house and are of the highest quality. These pellets contain 10 milligrams of the active ingredient (flubromazepam). Each pellet has a diameter of approximately 8 mm with a break line. These flubromazepam pellets are blistered in packs of 10 to ensure freshness, and orders of 5 or more blisters are delivered in a convenient box. 1V-LSD 150 MCG þynnur
Flubromazepam is a substance that is only sold for research purposes og er því ekki ætlað til neyslu.
Flubromazepam remains stable for up to 2 years when stored in the correct environment. Flubromazepam is intended for research purposes and not for human consumption. Therefore, it is important to store the product out of the reach of children and pets. 6-CL-ADBA
We offer high-quality research chemicals at a fair price. Your order is shipped within 24 hours every day. Order Flúbrómazepam safely and quickly.
Flubromazepam properties
Samheiti: Flúbrómazepam
CAS-númer: 2647-50-9
Formúla: 7-brómó-5-(2-flúorfenýl)-1,3-díhýdró-2H-1,4-bensódíazepín-2-ón
Mólmassi: 333,2 g/mól
Hreinleiki: >98%
Hættuyfirlýsing
Flubromazepam may cause respiratory irritation.
Flubromazepam may cause eye irritation.
Það er bannað að losa rannsóknarefni út í umhverfið.
Flubromazepam IN EYES: Rinse eyes gently with water for five minutes. Remove contact lenses, if present and easy to do .
Flubromazepam IN CONTACT WITH SKIN: Wash skin with soap and water.
IF INHALED Flubromazepam: Remove the victim to fresh air and keep the victim in a position comfortable for breathing.
